Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Ciba Geigy Holds The Line On Prices


In Business This Week

CIBA-GEIGY HOLDS THE LINE ON PRICES

Victims of high blood pressure can already choose from six ACE-inhibitors--the newest treatment for their ailment. That's why the market's newest entrant, Ciba-Geigy, is offering price protection for buyers of Lotensin, its ACE-inhibitor that went on the market in mid-July.

The plan works like this: A patient pays the wholesale price of the drug plus a standard pharmacy markup--ranging from 22% for a bottle of 30 pills to 5% for a 100-pill supply. In future years, Ciba-Geigy will reimburse patients for any price increase over and above that initial charge. The offer is a gamble, since the drug will have to meet an annual sales projection of $100 million if Ciba-Geigy is to make a profit on the scheme.EDITED BY HARRIS COLLINGWOOD


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus